Dr. Virginia Filiaci's headshot Dr. Virginia Filiaci's headshot

Virginia Filiaci


Specializing In:

Biostatistics Clinical Trial Design and Conduct Precision Medicine Gynecologic Oncology

About Virginia Filiaci


I began my career as a biostatistician at Roswell Park Comprehensive Cancer Center in 1990, working under Dr. Clara Bloomfield in the Department of Medicine. Four years later, I was given the opportunity to join a team of biostatisticians at the Statistical and Data Management Center for the NCI-funded Cooperative Group, Gynecologic Oncology Group (GOG). The center was housed at Roswell Park since the early 1970s and, in addition to biostatisticians, it included Data Management, IT, and Quality Assurance and Reporting teams. Under the mentorship of Drs. Blessing, Brady and Bundy, I was given the responsibility to design, analyze and report on phase 1-3 uterine cancer treatment trials as the GOG Uterine Corpus Committee statistician. In 2010 I was promoted to Associate Director of Biostatistics and Science and was given a joint appointment as a UB Research Assistant Professor. Later, in 2016, I became the Chief of the Division. In 2014, the federally funded component of the GOG Foundation united with two other Cooperative Groups (NSABP and RTOG) to form NRG Oncology at which time the GOG SDMC united with the two other SDMCs as the NRG Oncology SDMC. In 2017, I was given the title of Deputy Director of the NRG Oncology Statistics and Data Management Center.


Roswell Park Comprehensive Cancer Center

  • Chief, Clinical Trial Development Division
  • Biostatistics and Bioinformatics


Education and Training:

  • PhD - Biostatistics - University at Buffalo, Buffalo, NY
  • MA, BA - Mathematics - Potsdam College, Potsdam, NY

Professional Memberships:

  • American Society of Clinical Oncology
  • American Statistical Association
  • Buffalo-Niagara Chapter of the American Statistical Association
  • Society for Controlled Clinical Trials

Professional Experience:

  • Chief, Clinical Trial Development Division
  • Deputy Director, NRG Oncology Statistics and Data Management Center
  • UB Research Assistant Professor

Honors & Awards:

  • Delta Omega Public Health Honor Society, Gamma Lambda Chapter Inductee


Full Publications list on PubMed

1) Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O'Malley DM, Spirtos NM, Small W Jr, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019 Jun 13;380(24):2317-2326. doi: 10.1056/NEJMoa1813181. PubMed PMID: 31189035. PMCID: PMC6948006
2) Miller DS, Filiaci VL, Fleming GF, Mannel RS, Cohn D, Matsumoto T, Tewari KS, DiSilvestro PA, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Zaino RJ. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29. PMID: 33078978; PMCID: PMC7676887 Editor’s Pick.
3) Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ, Rutherford T, Spirtos NM, Terada K, Anderson PR, Brewster WR, Small W, Aghajanian CA, Miller DS. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019 Apr 17:JCO1801575. doi: 10.1200/JCO.18.01575. [Epub ahead of print] PMID: 30995174. PMCID: PMC6804858
4) Aghajanian, Filiaci V, Dizon DS, Carlson JW, Powell MA, Alvarez Secord A, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Rotmensch J, Gao J, Dao F, Soslow R, Lankes HA, Moore KN, Levine DA. A three arm randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for advanced or recurrent endometrial cancer, an NRG/Gynecologic Oncology Group Study. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. PubMed PMID: 29804638; PubMed Central PMCID: PMC6179372.
5) Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51.